IGH Naturals begins clinical trial for product to ease chemotherapy side effects
Rocklin-based IGH Naturals Inc., known for its nutritional supplements, has been approved to conduct a clinical study on its product Humolyte, aimed at reducing the harsh side effects of chemotherapy. The study will focus on the effectiveness of Humolyte in easing oral ulcers and gastrointestinal distress, two common and debilitating side effects experienced by chemotherapy patients.
Dr. Sourabh Kharait, CEO and founder of IGH Naturals, expressed optimism about the study’s potential impact. “Through this research, we aim to bring a tangible improvement to the quality of life for cancer patients by addressing some of the most debilitating side effects of chemotherapy,” Kharait said in a news release.
Currently, Humolyte is classified as a food product or supplement, but with successful study results, IGH hopes to officially make claims about its effectiveness for chemotherapy patients. The study has been approved by the Biomedical Research Alliance of New York LLC as part of an Institutional Review Board effort. IGH Naturals will provide 40 patients with six weeks of Humolyte products at no cost for the research. The company is actively collaborating with oncologists to identify suitable candidates for the trial.
Humolyte is designed to aid in hydration and protect the digestive system during chemotherapy, reducing the risk of nausea, vomiting, and diarrhea. IGH recommends patients start using Humolyte before beginning chemotherapy treatments, as once the side effects set in, they can be challenging to manage.
While IGH’s products, including Humolyte, are considered food products and not drugs, their synthesized oligosaccharides have been designated as "generally recognized as safe" (GRAS) by the FDA for oral consumption.
Founded in 2017 by Dr. Kharait, who holds both a medical degree in internal medicine and a Ph.D. in cellular and molecular pathology, IGH Naturals was established with the mission of providing hydration and supplements for medical patients without the need for intravenous treatment. In 2019, IGH launched Magnak, a magnesium-rich electrolyte hydration mix designed for athletes to improve muscle performance and reduce cramps.
The company, though small with a limited number of employees, has been steadily expanding its reach through sales on Amazon. All products are contract manufactured, and while IGH has opted not to disclose its revenue, the company’s innovations in both the medical and athletic hydration space continue to make an impact.
The clinical trial is open to eligible patients across the United States, marking a significant step forward for IGH Naturals as it seeks to validate the medical benefits of its products for chemotherapy patients.
To learn how HuMOLYTE can aid in hydrating patients during chemotherapy and alleviating chemotherapy side effects, visit here.
About Dr. Sourabh Kharait
Dr. Sourabh Kharait (MD / PhD) is Clinical Nephrologist and Medical Director of Clinical Trials at Summit Nephrology Medical Group, and the Founder and CEO of IGH Naturals, a platform company that designs Functional Foods and Nutritional products for athletes and patients with chronic diseases.
